info@cymabay.com
(510) 293-8800
Home
About
Overview
Management Team
Board of Directors
Careers
Clinical Trials
Pipeline
Overview
Seladelpar
Additional Programs
Expanded Access
Clinical Trials
Collaborations
News
Press Releases
Upcoming Events
Investors
Contact
Investors
Home
/
Investors
/
Press Releases
Press Releases
Overview
News / Events
Press Releases
Events
Presentations
Publications
Email Alerts
Company Information
Profile
Management Team
IR Contacts
FAQ
Financial Information
Financials
Quarterly Results
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Corporate Governance
Board of Directors
Board Committees
Governance Docs
Email Alerts
IR Contacts
RSS News Feed
All News
By Year:
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
5
Nov
CymaBay Reports Third Quarter 2019 Financial Results and Provides Corporate Update
4
Nov
CymaBay Therapeutics Reaches Target Enrollment in the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis
28
Oct
CymaBay Therapeutics to Report Third Quarter 2019 Financial Results on Tuesday, November 5
14
Oct
CymaBay Therapeutics to Present at the H.C. Wainwright 3rd Annual NASH Investor Conference
1
Oct
CymaBay Therapeutics Announces Presentations at The Liver Meeting® 2019
30
Sep
CymaBay Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
17
Sep
CymaBay Therapeutics Announces Departure of Chief Medical Officer
3
Sep
CymaBay Therapeutics to Present at Upcoming Investor Conferences in September
7
Aug
CymaBay Reports Second Quarter 2019 Financial Results and Provides Corporate Update
5
Aug
CymaBay Therapeutics Strengthens Management Team with Appointment of Janet Dorling as Chief Commercial Officer
<< Previous
1...
2
3
4
5
6
7
8
9
10
11
...24
Next >>
Show All
Scroll
